In trials that meant about a 15% reduction over 26 weeks, while sparing subcutaneous fat and lean muscle
Depending on the clinical picture, that typically includes: Relevant baseline bloodwork before starting IGF-1 dynamics where appropriate, so the response can be tracked rather than assumed Glucose and metabolic markers where relevant Follow-up adjustments based on results, tolerability, and goals A clear plan for duration and review rather than indefinite open-ended use This is also why CJC-1295 and Ipamorelin are often discussed alongside related options like Tesamorelin for visceral fat and metabolic goals
Synthetic control arms A statistical method used to estimate the outcomes of a treatment group in the absence of a traditional control group, wherein participants are not randomized to an active comparator or placebo, but data from such a group is constructed using either historical or external sources to closely resemble those undergoing treatment
Historically, a major research focus has been the anticancer effect of glucosinolates
Current studies highlight its potential as a selective model compound, though outcomes remain exploratory and require further inquiry to clarify mechanisms and implications